Download MendeleyAcyclic purine and pyrimidine nucleotide analogs as ecto-5'-nucleotidase (CD73) inhibitors.
Federico, S., Renn, C., Brehova, P., Janeba, Z., Moschutz, S., Sylvester, K., Shamleh, R.A., Baburi, H., Zimmermann, H., El-Tayeb, A., Strater, N., Muller, C.E.(2025) Eur J Med Chem 294: 117653-117653
- PubMed: 40378575
- DOI: https://doi.org/10.1016/j.ejmech.2025.117653
- Primary Citation of Related Structures:
9HJG - PubMed Abstract:
Ecto-5'-nucleotidase (CD73) is a novel target in cancer (immuno)therapy. Its blockade prevents the formation of immunosuppressive and cancer-promoting adenosine from AMP. Here, we report on the development of a series of small molecules that mimic adenine nucleotides, in which the ribose moiety was replaced by an alkyl chain. Its length was found to be crucial for potency. A crystal structure of the N 6 -disubstituted acyclic ADP analog 26 (N 6 -benzyl,N 6 -methyladenine-9-yl)pentyloxydiphosphonate) in complex with human CD73 revealed that the flexible pentyl linker adopts to interdomain rotation angles differing by up to 18.5°. The most potent CD73 inhibitor of the present series was analog 27 (N 6 -benzyl,N 6 -methyladenine-9-yl)hexyloxydiphosphonate, PSB-24000) which exhibited submicromolar potency at human CD73 (K i 563 nM at soluble CD73; K i 481 nM at membrane-bound CD73 of triple-negative breast cancer cells). Acyclic nucleotide analogs may be advantageous compared to the previously reported nucleotidic CD73 inhibitors due to their high chemical stability, and because less off-target effects are to be expected. The structure-activity relationships discovered in this study provide valuable insights which will be useful for the development of CD73 inhibitors as immunotherapeutic drugs.
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany; Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, I-34127, Trieste, Italy. Electronic address: sfederico@units.it.
Organizational Affiliation:
